Why are anti-obesity drugs stigmatized?

Expert Opinion on Drug Safety

Volumn 14, Issue 2, 2015, Pages 185-189

  Halpern, Bruno ^a   Halpern, Alfredo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anti obesity; Efficacy; Lorcaserin; Orlistat; Safety

Indexed keywords

ANTIOBESITY AGENT; LORCASERIN; PLACEBO; TETRAHYDROLIPSTATIN;

DRUG MISUSE; HUMAN; LIFESTYLE MODIFICATION; OBESITY; PRESCRIPTION; PRIMARY MEDICAL CARE; RECURRENT DISEASE; REVIEW; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; STEREOTYPING;

ANTI-OBESITY AGENTS; HUMANS; OBESITY; STEREOTYPING;

EID: 84921343633     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.995088     Document Type: Review

References (51)

1. Halpern A, Halpern B. Safety assessment of FDA approved (orlistat and lorcaserin) anti-obesity medications. Expert Opin Drug Saf. [Epub ahead of print]
2. Reuser M, Bonneux LG, Willekens FJ. Smoking kills, obesity disables: a multistate approach of the US Health and Retirement Survey. Obesity (Silver Spring) 2009;17(4):783-9
3. Allison DB, Fontaine KR, Manson JE, et al. Annual deaths attributable to obesity in the United States. JAMA 1999;282(16):1530-8
4. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014;311(1):74-86
5. Colman E, Golden J, Roberts M, et al. The FDA's assessment of two drugs for chronic weight management. N Engl J Med 2012;367(17):1577-9
6. Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults (US). Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. National Institutes of Health, National Heart, Lung, and Blood Institute; Bethesda, MD: 1998
7. Casazza K, Fontaine KR, Astrup A, et al. Myths, presumptions, and facts about obesity. N Engl J Med 2013;368(5):446-54
8. Middleton KM, Patidar SM, Perri MG. The impact of extended care on the long-term maintenance of weight loss: a systematic review and meta-analysis. Obes Rev 2012;13:509-17
9. Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369(2):145-52
10. Douketis JD, Macie C, Thabane T, et al. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond) 2005;29(10):1153-67
11. Aronne LJ. Obesity as a disease: etiology, treatment, and management considerations for the obese patient. Obes Res 2002(Suppl 2):95S-6S
12. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults. Report for the pnale members appointed to the eighth joint national committee (JNC8). JAMA 2014;311(5):507-20
13. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Assocation for the Study of Diabetes (EASD). Diabetes Care 2012;35(6):1364-79
14. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Assocation Task Force on Practice Guidelines. Circulation 2014;129(25 Suppl 2):S1-45
15. American Medical Association. Resolution 420 (A-13): recognition of obesity as a disease. Proceedings of the House of Delegates 162nd Annual Meeting; 15-19 June 2013. Available from: http://www.ama-assn.org/assets/meeting/2013a/a13-addendum-refcommd.pdf June 19, 2013 [Accessed 14 August 2014]
16. Woloshin S, Schwartz LM. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings? JAMA Intern Med 2014;174(4):615-19
17. Katz DL. Perspective: obesity is not a disease. Nature 2014;508:S57
18. Puhl RM, Brownell KD. Bias, discrimation, and obesity. Obes Res 2001;9:788-905
19. Bonfiglioli MF, Smith BJ, King LA, et al. Choice and voice: obesity debates in television news. Med J Aust 2007;187:442-5
20. Kim S-H, Willis LA. Talking about obesity: news framing of who is responsible for causing and fixing the problem. J Health Commun 2007;12:359-76
21. Dansinger ML, Tatsioni A, Wong JB, et al. Meta-analysis: the effect of dietary counseling for weight loss. Ann Intern Med 2007;3147(1):41-50
22. Pagoto SL, Appelhans BM. A call for an end to the diet debates. JAMA 2013;310(7):687-8
23. Klem ML, Wing RR, McGuire MT, et al. A descriptive study of individuals successful at long-term maintenance of substantial weight loss. Am J Clin Nutr 1997;66(2):239-46
24. Barbano D. Inibidores de apetite devem ser proibidos? Sim. Folha de São Paulo. May 17th, 2014
25. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393-403
26. Wing RR, Lang W, Wadden TA, et al. Look AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011;34(7):1481-6
27. Jansen MD, Ryan DH, Apovian CM, et al. AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Obesity (Silver Spring) Circulation 2014;129(25 Suppl 2):S139-40
28. Wadden TA, Volger S, Sarwer DB, et al. A two-year randomized trial of obesity treatment in primary care practice. N Engl J Med 2011;365:1969-79
29. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcome in overweight and obese subjects. N Engl J Med 2010;363(10):905-17
30. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012;36:843-54s
31. Smith SR, Weissman NJ, Anderson CM. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363(3):245-56
32. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial. Obesity (Silver Spring) 2012;20(2):330-42
33. Sjöstrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352(9123):167-72
34. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288:1723-7
35. Samocha-Bonet D, Dixit VD, Kahn CR, et al. Metabolically heath and unhealthy obese - the 2013 Stock Conference report. Obes Rev 2014;15(9):697-708
36. Chang Y, Kim BK, Yun KE, et al. Metabolically-healthy obesity and coronary artery calcification. J Am Coll Cardiol 2014;63(24):2679-86
37. Hinnouho GM, Czernichow S, Dugravot A, et al. Metabolically healthy obesity and risk of mortality: does the definition of metabolic health matter? Diabetes Care 2013;36:2294-300
38. Wadden TA, Neiberg RH, Wing RR, et al. Four-year weight losses in the LOOK AHEAD study: factors associated with long-term success. Obesity (Silver Spring) 2011;19(10):1987-98
39. Khandalavala BN, Rojanala A, Geske JA, et al. Obesity bias in clinical care providers. Fam Med 2014;46(7):532-5
40. Bray GA. Are non-prescription medications needed for weight control? Obesity (Silver Spring) 2008;16(3):509-14
41. St John Sutton M. Silver lining to the cloud over anorexogen-related cardiac valvulopathy? Ann Intern Med 2011;134(4):335-7
42. Martins Mdo C, Souza Filho MD, Moura FS, et al. Use of anti-obesity drugs among college students. Rev Assoc Med Bras 2011;57(5):570-6
43. Jeffers A, Benotsch EG, Koester S. Misuse of prescription stimulants for weight loss, psychosocial variables, and eating disordered behaviors. Appetite 2013;65:8-13
44. Noto AR, Baptista MC, Faria ST, et al. Drugs and health in the Brazilian press: an analysis of articles published in newspapers and magazines. Cad Saude Publica 2003;19(1):69-79
45. Li MF, Cheung BM. Rise and fall of anti-obesity drugs. World J Diabetes 2011;2(2):19-23
46. Di Dalmazi G, Vicennati V, Pasquali R, et al. The unrelenting fall of the pharmacological treatment of obesity. Endocrine 2013;44(3):598-609
47. McBride BF, Karapanos A, Krudysz A, et al. Electrocardiographic and hemodynamic effects of a multicomponent dietary supplement containing ephedra and caffeine: a randomized controlled trial. J Am Med Assoc 2004;291:216-21
48. Connoley IP, Liu YL, Frost I, et al. Thermogenic effects of sibutramine and its metabolites. Br J Pharmacol 1999;126:1487-95
49. Connolly HM, Crary JL, McGoon MD. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8
50. Topol EJ, Bousser MG, Fox KA. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomized, multicenter, placebocontrolled trial. Lancet 2010;376(9740):517-23
51. Caterson ID, Finer N, Coutinho W. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab 2012;14:523-30